Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS.

Cancer Res. 2003 Jun 1;63(11):2742-6.

3.

Pten signaling in gliomas.

Knobbe CB, Merlo A, Reifenberger G.

Neuro Oncol. 2002 Jul;4(3):196-211. Review.

4.

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

Panwalkar A, Verstovsek S, Giles FJ.

Cancer. 2004 Feb 15;100(4):657-66. Review.

5.

Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.

Abel TW, Baker SJ, Fraser MM, Tihan T, Nelson JS, Yachnis AT, Bouffard JP, Mena H, Burger PC, Eberhart CG.

J Neuropathol Exp Neurol. 2005 Apr;64(4):341-9. Review.

PMID:
15835270
6.

The biology and clinical relevance of the PTEN tumor suppressor pathway.

Sansal I, Sellers WR.

J Clin Oncol. 2004 Jul 15;22(14):2954-63. Review.

PMID:
15254063
7.

PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.

Paez J, Sellers WR.

Cancer Treat Res. 2003;115:145-67. Review. No abstract available.

PMID:
12613196
8.

Will kinase inhibitors make it as glioblastoma drugs?

Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF.

Curr Top Microbiol Immunol. 2012;355:135-69. doi: 10.1007/82_2011_178. Review.

9.

Restraining PI3K: mTOR signalling goes back to the membrane.

Harrington LS, Findlay GM, Lamb RF.

Trends Biochem Sci. 2005 Jan;30(1):35-42. Review.

PMID:
15653324
10.

Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype?

Finnberg N, El-Deiry WS.

Cancer Biol Ther. 2004 Jul;3(7):614-6. Epub 2004 Jul 24. Review.

PMID:
15254408
11.

PI3K/AKT signaling and systemic autoimmunity.

Patel RK, Mohan C.

Immunol Res. 2005;31(1):47-55. Review.

PMID:
15591622
12.

Signaling inhibition with radiation in colorectal cancer: clinical trials.

McKenna WG, Muschel RJ, Gupta A, Hahn S, Bernhard EJ.

Semin Oncol. 2003 Jun;30(3 Suppl 6):56-67. Review.

PMID:
12802796
13.

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS.

Neurotherapeutics. 2009 Jul;6(3):500-12. doi: 10.1016/j.nurt.2009.04.008. Review.

14.

Incorporating molecular tools into early-stage clinical trials.

Weil RJ.

PLoS Med. 2008 Jan 22;5(1):e21. doi: 10.1371/journal.pmed.0050021. Review. No abstract available.

15.

Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells.

Takahashi K, Murakami M, Yamanaka S.

Biochem Soc Trans. 2005 Dec;33(Pt 6):1522-5. Review.

PMID:
16246160
16.

The multiple roles of phosphoinositide 3-kinase in mast cell biology.

Kim MS, RĂ¥dinger M, Gilfillan AM.

Trends Immunol. 2008 Oct;29(10):493-501. doi: 10.1016/j.it.2008.07.004. Epub 2008 Sep 3. Review.

17.

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.

Mellinghoff IK, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81. Review.

18.

Mammalian target of rapamycin.

Meric-Bernstam F, Mills GB.

Semin Oncol. 2004 Dec;31(6 Suppl 16):10-7; discussion 33. Review.

PMID:
15799239
19.

PI3Kinase signaling in glioblastoma.

Lino MM, Merlo A.

J Neurooncol. 2011 Jul;103(3):417-27. doi: 10.1007/s11060-010-0442-z. Epub 2010 Nov 10. Review.

20.

Current clinical development of PI3K pathway inhibitors in glioblastoma.

Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK.

Neuro Oncol. 2012 Jul;14(7):819-29. doi: 10.1093/neuonc/nos117. Epub 2012 May 22. Review.

Supplemental Content

Support Center